RxDoctor Payments Data

Mara Bactad

Family · Oxnard, CANPI 1164157913

Payments from drug & device makers

$2,560in general payments, 2019–2025

Across 85 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$773
  • Amgen$329
  • Edwards Lifesciences$277
  • Novartis$211
  • Novo Nordisk$187
  • Sanofi$143
  • plus $641 from 9 others

What the payments were for

  • Food & beverage$2,52899%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,560 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$161,472
Medicare patients
651
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$281,387
EntrestoSacubitril/Valsartan188$204,320
XareltoRivaroxaban106$146,446
JanuviaSitagliptin Phosphate57$69,287
OzempicSemaglutide59$61,388
JardianceEmpagliflozin38$52,643
FarxigaDapagliflozin Propanediol37$42,368
BrilintaTicagrelor42$40,877
TrulicityDulaglutide37$37,697
Repatha SureclickEvolocumab23$29,727
TradjentaLinagliptin16$20,496
Bydureon BciseExenatide Microspheres18$16,279
Amiodarone Hcl176$13,512
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$10,220
Janumet XrSitagliptin Phos/Metformin Hcl11$7,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$211$204,320188 claims
AstraZenecaFarxiga, Brilinta$773$83,24579 claims
MerckJanuvia, Janumet Xr$107$76,61468 claims
Boehringer IngelheimJardiance, Tradjenta$120$73,13954 claims
Novo NordiskOzempic$187$61,38859 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →